Evaluation of Dose-Adjusted EPOCH-R Compared with R-CHOP for the Treatment of High-Risk, Aggressive B-Cell Lymphomas: A Single-Center Experience

被引：1
|
作者：
Rockwell, Sarah J.
Richter, Katherine A.
Caddell, Ryan J.
Chavez, Julio C.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140085
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma
    Malenda, Agata
    Kolkowska-Lesniak, Agnieszka
    Pula, Bartosz
    Dlugosz-Danecka, Monika
    Chelstowska, Monika
    Konska, Agnieszka
    Giza, Agnieszka
    Lech-Maranda, Ewa
    Jurczak, Wojciech
    Warzocha, Krzysztof
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (01) : 59 - 66
  • [2] Dose-Adjusted EPOCH-R is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma
    Ma'koseh, Mohammad
    Yaseen, Abeer
    Abu Abed, Nebras
    Shahin, Omar
    Abufara, Alaa
    Halahleh, Khalid
    Al-Rwashdeh, Mohammad
    Rahman, Zaid Abdel
    Alyaqoub, Maram
    Al-rabi, Kamal
    Abdel-Razeq, Hikmat
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S488 - S488
  • [3] DOSE-ADJUSTED EPOCH-R: A RETROSPECTIVE STUDY IN THE TREATMENT OF AGGRESSIVE LYMPHOMAS
    Anichini, M.
    Kovalchuk, S.
    Puccini, B.
    Romano, I.
    Mazzoni, C.
    Galli, E.
    Bosi, A.
    HAEMATOLOGICA, 2019, 104 : 168 - 168
  • [4] Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas
    Lakhotia, Rahul
    Melani, Christopher
    Dunleavy, Kieron
    Pittaluga, Stefania
    Desai, Sanjal
    Ahlman, Mark A.
    Lucas, Nicole
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Wilson, Wyndham H.
    Roschewski, Mark
    LEUKEMIA & LYMPHOMA, 2025,
  • [5] Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
    Bhagirathbhai Dholaria
    Yenny Alejandra Moreno Vanegas
    Nancy Diehl
    Aaron C. Spaulding
    Sue Visscher
    Han W. Tun
    Sikander Ailawadhi
    Prakash Vishnu
    Clinical Hematology International, 2020, 2 (3) : 117 - 124
  • [6] Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?
    Chamuleau, Martine E. D.
    LANCET HAEMATOLOGY, 2021, 8 (11): : E781 - E783
  • [7] Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas
    Desai, Sanjal
    Melani, Christopher
    Dunleavy, Kieron
    Pittaluga, Stefania
    Ahlman, Mark A.
    Lucas, Andrea Nicole
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Wilson, Wyndham
    BLOOD, 2019, 134
  • [8] Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
    Lim, Kenneth J. C.
    Filshie, Robin
    LANCET HAEMATOLOGY, 2023, 10 (12): : E942 - E943
  • [9] Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas
    Gharwan, Helen
    Lai, Catherine
    Grant, Cliona
    Dunleavy, Kieron
    Steinberg, Seth M.
    Shovlin, Margaret
    Fojo, Tito
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1616 - 1624
  • [10] The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R
    Wilson, WH
    Gutierrez, M
    O'Connor, P
    Frankel, S
    Jaffe, E
    Chabner, BA
    Grossbard, ML
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 41 - 47
12345